MedTrace Logo

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-23

No results posted yet for this study

Summary

Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. The investigators plan to use Platelet Aggregometry and Thromboelastography (TEG) to evaluate the effect of ketorolac on platelets.

Conditions

  • Analgesia, Obstetrical
  • Coagulation Defect; Postpartum
  • Nonsteroidals (NSAIDs)Toxicity
  • Postpartum Hemorrhage
  • Postoperative Pain
  • Ketorolac Adverse Reaction
  • Blood Loss, Postoperative

Interventions

DRUG

Ketorolac Tromethamine 30 MG/ML

Ketorolac 30 mg

DRUG

Placebos

Normal Saline

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2022-02-03
Completion
2024-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03805607 on ClinicalTrials.gov